Showing 1 - 11 results of 11 for search 'Mark T. Orr', query time: 0.04s Refine Results
  1. 1
    The theory of reasoned action as parallel constraint satisfaction: towards a dynamic computational model of health behavior.

    The theory of reasoned action as parallel constraint satisfaction: towards a dynamic computational model of health behavior. by Mark G Orr, Roxanne Thrush, David C Plaut

    Published 2013-01-01
    Get full text
    Article
  2. 2
    Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice.

    Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice. by Mark T Orr, Kurt H Edelmann, Jeffrey Vieira, Lawrence Corey, David H Raulet, Christopher B Wilson

    Published 2005-09-01
    Get full text
    Article
  3. 3
    Formulated Phospholipids as Non-Canonical TLR4 Agonists

    Formulated Phospholipids as Non-Canonical TLR4 Agonists by Hong Liang, William R. Lykins, Emilie Seydoux, Jeffrey A. Guderian, Tony Phan, Christopher B. Fox, Mark T. Orr

    Published 2022-11-01
    Get full text
    Article
  4. 4
    The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.

    The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. by Natasha Dubois Cauwelaert, Anthony L Desbien, Thomas E Hudson, Samuel O Pine, Steven G Reed, Rhea N Coler, Mark T Orr

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Development and function of CD94-deficient natural killer cells.

    Development and function of CD94-deficient natural killer cells. by Mark T Orr, Jun Wu, Min Fang, Luis J Sigal, Pieter Spee, Thomas Egebjerg, Erik Dissen, Sigbjørn Fossum, Joseph H Phillips, Lewis L Lanier

    Published 2010-12-01
    Get full text
    Article
  6. 6
    Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment

    Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment by Sasha E. Larsen, Susan L. Baldwin, Mark T. Orr, Valerie A. Reese, Tiffany Pecor, Brian Granger, Natasha Dubois Cauwelaert, Brendan K. Podell, Rhea N. Coler

    Published 2018-05-01
    Get full text
    Article
  7. 7
    Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

    Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. by Susan L Baldwin, Valerie A Reese, Sasha E Larsen, Elyse Beebe, Jeff Guderian, Mark T Orr, Christopher B Fox, Steven G Reed, Rhea N Coler

    Published 2021-01-01
    Get full text
    Article
  8. 8
    Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy

    Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy by Mayuresh M. Abhyankar, Mark T. Orr, Mark T. Orr, Robert Kinsey, Sandra Sivananthan, Andrew J. Nafziger, David N. Oakland, Mary K. Young, Laura Farr, Md Jashim Uddin, Jhansi L. Leslie, Stacey L. Burgess, Hong Liang, Ines De Lima, Elise Larson, Jeffrey A. Guderian, Susan Lin, Aaron Kahn, Prakash Ghosh, Sierra Reed, Mark A. Tomai, Karl Pedersen, William A. Petri, Christopher B. Fox, Christopher B. Fox

    Published 2021-06-01
    Get full text
    Article
  9. 9
    Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine

    Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine by Michelle C. Archer, Joseph McCollum, Christopher Press, Timothy S. Dutill, Hong Liang, Dawn Fedor, Liam Kapilow-Cohen, Alana Gerhardt, Tony Phan, Edward H. Trappler, Mark T. Orr, Ryan M. Kramer, Christopher B. Fox

    Published 2023-06-01
    Get full text
    Article
  10. 10
    Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions

    Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions by Karl J. Fisher, Robert Kinsey, Raodoh Mohamath, Tony Phan, Hong Liang, Mark T. Orr, William R. Lykins, Jeffrey A. Guderian, Julie Bakken, David Argilla, Gabi Ramer-Denisoff, Elise Larson, Yizhi Qi, Sandra Sivananthan, Karina Smolyar, Darrick Carter, Christopher J. Paddon, Christopher B. Fox

    Published 2023-02-01
    Get full text
    Article
  11. 11
    Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191

    Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191 by Margaret C. Lunn-Halbert, George S. Laszlo, Sarah Erraiss, Mark T. Orr, Heidi K. Jessup, Heather J. Thomas, Henry Chan, Mahan A. Jahromi, Jonathan Lloyd, Ann F. Cheung, Gregory P. Chang, Tanmay Dichwalkar, Daniel Fallon, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter

    Published 2024-02-01
    Get full text
    Article

Search Tools: